AnnJi Pharmaceutical überführt AJ201 in die zulassungsrelevante Phase-3-Studie „ROMA-KD" zur Behandlung der spinalen und bulbären Muskelatrophie (SBMA)

AJ201 (rosolutamide) is described as the world's only known Phase 3 investigational therapy for spinal and bulbar muscular atrophy (SBMA). It is an oral small-molecule drug intended to target multiple disease mechanisms; the excerpt provides no efficacy results or other trial data.